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5 (Corbett et al., 1993) . The identification of novel stable agonists, with improved pharmacological properties, is therefore highly desirable to study the biological activity of delta receptors in physiological context. (Filliol et al., 2000; Kieffer and Gavériaux-Ruff, 2002) .
Basal activity of GPCRs is not easily measurable and the search for inverse agonists has been facilitated by the construction of Constitutively Active Mutant (CAM) receptors where potency and efficacy of inverse agonists are enhanced (Rossier et al., 1999) . In a previous study, we have used a random mutagenesis approach to identify human delta CAM receptors (Decaillot et al., 2003) . Here we have investigated the in vitro pharmacological activity of a series of delta antagonists from distinct structural families at these CAM receptors. Using two different functional assays, we have examined properties of a number of commercially available delta antagonists.
We have tested four alkaloid opioids that have been classically defined as antagonist compounds, and are widely used in pharmacological studies. These compounds are NLX, considered the reference opioid antagonist, as well as NTI, NTB and BNTX that exhibit reasonable delta selectivity (Corbett et al., 1993) and are structurally related. We also have included delta compounds that have been developed more recently in the search for compounds with better delta selectivity (see Fig. 1 ). Among them was a new series of NTI derivatives (Schmidhammer et al., 1998) including HS-378, HS-414, HS-464, HS-510A, HS-531 and HS-595. TIPP (Schiller et al., 1992) , which was the first peptide from a new class of highly delta selective antagonists, and TICP(Ψ) a more hydrophobic and stable derivative (Schiller et al., 1999) were also tested. Further we have studied three compounds from the Dmt-Tic family where 2', 6' methylation of the N-terminal tyrosine residue (Dmt) is combined to the heteroaromatic residue Tic, leading to a class of pseudo-dipeptides with high delta selectivity and antagonist properties (Bryant et al., 2003; Bryant et al., 1998 ; Salvadori JPET #77321 8 cells. Transfection was performed in DMEM 10% FCS with antibiotics and cells harvested after forty eight hours. For the SEcreted Alkaline Phosphatase (SEAP) assay, all WT and CAM receptors were expressed transiently in HEK 293 cells as previously described (Befort et al., 2001b ) with a slightly modified procedure. Briefly, HEK 293 cells were plated in 96 well plates (Biocoat, Falcon) at a density of 35 000 cells / well on the day before transfection.
Cells were co-transfected at about 70 % confluency with the reporter gene pCRE-SEAP (Clontech, 1 µg / well) and WT or mutated delta receptor plasmid DNA (0.15 µg / well) using Jet-PEI reagent. Thirty-two hours after transfection, cells were serum-starved overnight and subjected to the SEAP test.
Ligand binding assay. HEK 293 cells expressing WT and CAM receptors stably or
transienly were harvested for membrane preparation according to the described procedure (Befort et al., 2001b) . Membranes were resuspended in 50 mM Tris HCl pH 7. 4 buffer by filtration through 0.1% polyethyleneimine-presoaked microplate filters (Unifilter GF/B) using a Filtermate Harvester (PerkinElmer). Microplates were dried, then wells were covered by 40 µl scintillation cocktail (PerkinElmer) and counted in a Microplate Scintillation/Luminescence Counter (Packard) using the TopCount-NXT software. Assays This article has not been copyedited and formatted. The final version may differ from this version. To further examine bioactivity of the delta opioid compounds, we used the more As in our first experiment (Fig 2) , the most active inverse agonist was N,N(CH 3 ) 2 -Dmt- , 2003) , and where inverse agonists showed best activities in this study (Fig. 3) .
Dose-responses to Dmt-Tic compounds at WT, M262T, Y308H and C328R
mutant receptors. To fully characterize agonism and inverse agonism of the most active delta compounds, we first determined their binding affinities at the different receptors (Table   1) . We have shown above that opioid binding at M262T delta receptor is comparable to WT receptor. Similarly, Ki values were unchanged at the C328R mutant, consistent with the notion that M262 and C328 residues are located on the cytoplasmic face of the receptor and unlikely involved in ligand binding (Decaillot et al., 2003) . In contrast binding affinities were substantially decreased at the Y308H receptor. This was expected because this residue is centrally located within the ligand binding pocket and known to influence opioid affinity (Befort et al., 1996; Befort et al., 1999) . Affinities to Y308H, however, remained measurable and dose-responses were also performed for this mutant.
Further, we determined potencies and efficacies using the two functional assays at the selected receptors. 174868 efficacies (E max ) were 76.9 ± 2.4 % (WT, n = 2), 73.9 ± 2.4 % (M262T, n = 4), 92.8 ± 2.2 % (Y308H, n = 2), 68.5 ± 2.6 % (C328R, n = 2) of basal values. E max in the SEAP test were 147.5 ± 21.5 % (WT, n = 3), 170.1 ± 9.5 (M262T, n = 5), 174.2 ± 12.7 % (Y308H, n = 3) and 159.5 ± 21.8 % (C328R, n = 3) of FK-stimulated signal. Potencies could not be determined accurately, reflecting the extremely low affinity of ICI 174864 compound toward WT and mutant delta receptors (> 400 nM, Table 1 ) compared to the other delta compounds.
Potencies and efficacies of N,N(CH 3 ) 2 -Dmt-Tic-NH 2 are shown in Table 2 . Inverse agonism of this compound was significant at the WT receptor in the two functional assays.
Efficacies were consistently higher at CAM receptors compared to WT, reaching 63.8 ± 2. The closely related Dmt-Tic-OH compound showed similar properties ( Table 2 ).
Potencies and efficacies were comparable to those of N,N(CH 3 ) 2 -Dmt-Tic-NH 2 at the WT receptor, but tended to be lower at mutant receptors particularly in the SEAP assay. Together with our previous observation of an overall lower efficacy across the twenty-seven mutant receptors (Fig 3) , it seemed that inverse agonism was slightly less robust for this compound.
Adding to this, results from Dmt-Tic-OH were generally less reliable across experiments (not shown), probably due to lower stability of the compound which forms a diketopiperazine (Balboni et al., 1997; Capasso et al., 1995) and subsequently loses activity (Balboni et al., 1997 
Dose-responses of TICP(Ψ) at WT, M262T, Y308H and C328R mutant receptors.
Although inverse agonist activity was detected at saturating concentrations (Fig 2 and 3) , and although affinities at all the receptors were in the nanomolar range ( experiments (WT, 79.1 ± 1.9 %, n=2; M262T, 77.3 ± 1.8 %, n = 7; C328R, 73.8 ± 3.6 %, n = 3), demonstrating negative effect of this compound at these mutants. Interestingly TICP(Ψ) was extremely active at the Y308H receptor (Fig. 5) compounds.
An innovative aspect of this study is the use of CAM delta receptors to better assess inverse agonism of delta opioid compounds. Indeed, when the fifteen compounds were screened for negative activity, stronger activities were detected at the M262T mutant compared to WT receptor. This demonstrates that, as was shown for other GPCRs (Behan and Chalmers, 2001; Rossier et al., 1999) , a CAM delta receptor is a better detector of inverse agonism than the WT receptor. Confirming this, inverse agonist efficacies of the various compounds were generally comparable at the WT receptor, whereas partial and full inverse agonism could be distinguished at the several CAM delta receptors, when full dose-responses were performed (see Fig. 4 and 5).
The inverse agonist activity of ICI 174864 at the WT receptor appeared modest in our expression system, compared to previous studies that have used other cellular models (see introduction and references therein). Replacing Na + by K + ions for example, which successfully increased ICI 174864 activity in the case of excitable cells such as NG108-15 (Costa and Herz, 1989; Szekeres and Traynor, 1997) or GH3 cells (Liu and Prather, 2002) This article has not been copyedited and formatted. The final version may differ from this version. , 1995) . In addition, because the N-methylation augments hydrophobicity and prevents spontaneous cyclization (Bryant et al., 2003) , N,N(CH 3 ) 2 -Dmt-Tic-NH 2 is considered a stable compound, (Bryant et al., 2003) . Altogether therefore N,N(CH 3 ) 2 -Dmt-Tic-NH 2 appears the best pharmacological tool to explore the spontaneous activity of delta receptors.
Peptides from the TIPP family, showed unanticipated activities. TIPP was originally developed as a delta opioid antagonist (Schiller et al., 1992) . Consistent with this observation, TIPP was inactive in our [ 35 S]GTPγS binding assay. However in more recent studies, Martin and collaborators reported that TIPP could show agonistic properties in several cell lines using cAMP measurements (Martin et al., 2001 ). In addition, the latter authors showed that, in GH3 cells, TIPP exhibited inverse agonist or agonist properties, depending on whether the end-point measurement was performed early (receptor binding) or late (cAMP response) along the signaling cascade (Martin et al., 2002) . In line with these observations, we found agonistic properties for TIPP in the SEAP reporter gene assay which is sensitive to cAMP levels. Together with the study by Martin and collaborators therefore, our data suggest that TIPP may activate receptors to a small extend, and that the agonistic nature of TIPP is revealed after signal amplification only. This activity however may not be easily detectable since Pineyro and collaborators showed no TIPP-induced modifications of cAMP levels when the delta receptor was expressed in HEK 293 cells (Pineyro et al., 2001) . Differences between the study of Pineyro and our study may arise from distinct assay conditions. Whether TIPP behaves as agonist or inverse agonist under physiological conditions remains to be explored.
TICP(Ψ) was derived from TIPP by reduction of the peptide bound between Tic 2 and Phe 3 and saturation of the Phe 3 aromatic ring, leading to a chemically stable pseudopeptide with high delta selectivity (K i delta 0.259 nM; K i mu 1050 nM, (Schiller et al., 1996) . Like TIPP, TICP(Ψ) was reported to be a potent antagonist (Schiller et al., 1999) . In their study reported that TICP(Ψ) acted as full inverse agonist (similar to ICI 174864) for the cAMP response (Pineyro et al., 2001 ). In our study TICP(Ψ) showed only modest negative activity at the WT delta receptor, although we used a similar expression system and a similar end-point measurement. Clearly the detection of negative activity is dependent on the exact assay conditions. TICP(Ψ) nevertheless exhibited inverse agonism at the mutant Y308H receptor in our study. In fact, not only TICP(Ψ) but also the two Dmt-Tic compounds behaved as full inverse agonists at this receptor, while ICI 174864 activity was low. The Y308H receptor, therefore, seemed particularly responsive to peptides from the TIPP and Dmt-Tic families. The reason why TICP(Ψ) showed strong inverse agonism at this receptor, and more generally, why the pseudopeptides were highly active at the Y308H receptor remains unexplained. In contrast to mutations M262T and C328R, this mutation is located centrally within the binding pocket and drastically modifies opioid binding (Befort et al., 1996; Befort et al., 1999) . Specific atomic interactions may take place between these inverse agonists and the signaling core of the receptor (Tm 3 / Tm 6 / Tm 7), (Decaillot et al., 2003) that strongly favor the inactive receptor conformation. 3D-Modeling studies, in the future, may clarify specific structural features within the TICP(Ψ) -Y308H receptor complex.
Labarre et al. showed weak partial inverse agonism for the NTI derivative HS-378 (Labarre et al., 2000) . Our data showed no activity for this compound, as well as for a set of five closely related HS compounds, at the CAM M262T receptor. We even observed weak partial agonism at the WT receptor for most of them. Together, it seems that NTI and NTI derivatives (HS compounds) are weakly active at the delta receptor, and this activity could be either slightly negative (Labarre et al., 2000) , neutral or slightly positive (this study)
depending on the experimental system. Compared to ICI 174864 and the two active Dmt-Tic compounds, these compounds could therefore be considered as neutral ligands.
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